Rezatapopt Monotherapy Interim Data From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced September 16, 2025
Radiance Biopharma signs Exclusive License Agreement with Novatim Immune Therapeutics for RB-601™ (KY-0301), the c-MET/EGFR-targeting ADC September 10, 2025
Silexion Therapeutics Announces Selection of CRO to Support Upcoming Ph 2/3 Clinical Trials for SIL204 September 10, 2025
WCLC 2025: Interim Ph 2 Data for Pumitamig (BNT327/BMS986545) in Patients with ES-SCLC Shows Encouraging Antitumor Activity September 9, 2025
First cohort in Ph 1 trial of 177Lu-AKIR001 completed in patients with solid tumors September 3, 2025
SAKK 66/17 Ph 1b/2a Clinical Trial of IP-001 for Treatment of Solid Tumors Completed September 3, 2025
FDA INTERACT meeting completed in preparation to advance TBC-1 toward IND-enabling studies September 3, 2025
Incyclix Bio Secures $11.25M Series B Extension for Ph 1/2 Trial of INX-315 in CDK4/6i-Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors August 26, 2025
FDA IND application for ST-01156 Ph 1 trial in patients with advanced solid tumor and heme malignances August 19, 2025
Strand Therapeutics Raises $153M Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline August 12, 2025
First Patient Dosed in Ph 1 Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors August 12, 2025
FDA clears IND for Ph 2 trials for RC148 in multiple advanced malignant solid tumors in the US August 11, 2025
CBX-663 nominated for the treatment of a broad range of solid tumor and heme malignancies July 29, 2025
Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach July 29, 2025
